The Food and Drug Administration (FDA) took significant action against deceptive pharmaceutical advertising on Tuesday by sending thousands of warning letters and about 100 cease-and-desist letters to drug companies. The FDA’s initiative aims to curb misleading practices in the industry.

Additionally, the FDA plans to address the “adequate provision” loophole established in 1997. This loophole allowed drug companies to offer only brief safety warnings in broadcast and digital ads while directing consumers to external sources such as websites or phone lines for full risk details. Rulemaking efforts will focus on closing this gap.

President Donald Trump highlighted these efforts by signing a presidential memorandum aimed at enhancing transparency in prescription drug advertisements. This memorandum mandates federal regulators to enforce stronger transparency measures.

Trump signs action to strengthen prescription drug ad requirements

The directive specifically instructs the Department of Health and Human Services to ensure that direct-to-consumer drug advertising is both transparent and accurate. The Food and Drug Administration is tasked with rigorously enforcing the Federal Food, Drug, and Cosmetic Act’s advertising regulations for prescription drugs.

The memorandum emphasizes the need to increase the visibility of information concerning risks linked to prescription drugs in their advertisements, within legal limits.

“Pharmaceutical ads hooked this country on prescription drugs,” remarked Health and Human Services Secretary Robert F. Kennedy Jr. “We will dismantle this chain of misleading practices and make it mandatory for drug companies to fully disclose all critical safety information in their advertisements.”

Agency moves to close 1997 loophole allowing minimal safety disclosures  

The crackdown comes as the FDA has scaled back enforcement in recent decades. The agency once sent more than 100 warning letters annually to pharmaceutical companies for misleading advertising but sent only one in 2023 and zero in 2024, according to the FDA.

FDA Commissioner Marty Makary said the agency has been too permissive with misleading advertisements that distort doctor-patient relationships and increase demand for medications regardless of clinical need.

Drug companies spend up to 25% of their budgets on advertising, he noted in a press release.

A 2024 study found that while 100% of pharmaceutical social media posts highlight drug benefits, only 33% mention potential harms.

Additionally, 88% of advertisements for top-selling drugs are posted by individuals and organizations that fail to follow FDA guidelines requiring balanced information.

The regulatory changes will require drug companies to include full safety warnings, contraindications and common precautions directly in their advertisements, reversing the 1997 policy that allowed companies to provide abbreviated risk statements and refer consumers elsewhere for complete information.

Research cited by the administration shows direct-to-consumer advertising drove about 31% of the rise in U.S. drug spending since 1997. Patients who asked physicians for an advertised drug were about 17 times more likely to receive a prescription than those who didn’t ask, studies found.

Social media influencers to be monitored over paid promotions

The FDA said it is deploying artificial intelligence and other technology to monitor drug advertisements across all platforms, including social media, where paid influencer promotions have blurred the lines between editorial content and pharmaceutical advertising.

Current law requires drug advertisements to present balanced information about risks and benefits, avoid exaggerating benefits, properly disclose financial relationships and include information about major side effects.

The president noted that while Congress gave the FDA authority to regulate prescription drug advertising in 1962, the agency’s requirements have “permitted drug companies to include less information, particularly in broadcast advertising” as drug manufacturer advertising has increased dramatically in recent decades.